Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

NeoGenomics

Rank#4649

Market Cap2.36B

CountryUnited States

Summary

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

History

NeoGenomics was founded in 2001 by a group of oncologists, pathologists, and entrepreneurs with a passion for improving patient care through improved molecular diagnostics. Initially, NeoGenomics prepared and interpreted a variety of clinical testing including cytogenetics, disomy analyses, FISH, and CGH arrays. After years of investing in inventory, infrastructure and personnel, the company has become a full-service provider of clinical laboratory services for pathologists, oncologists, urologists and other clinical authorities.

Mission

We save lives by improving patient care.

Vision

By providing uncompromising quality, exceptional service and
innovative solutions, we will be the world’s leading cancer testing and information company.

References

https://en.wikipedia.org/wiki/NeoGenomics

https://in.investing.com/equities/neogenomics-inc

https://finance.yahoo.com/quote/NEO/profile?p=NEO

https://www.comparably.com/companies/neogenomics-laboratories/mission

https://www.crunchbase.com/organization/neogenomics-laboratories

https://sec.report/CIK/0001077183

https://companiesmarketcap.com/

https://www.neogenomics.com

Leadership team

Mr. George A. Cardoza (Pres & COO of Lab Operations)

Ms. Kathryn B. McKenzie (Interim Chief Culture Officer, Chief Sustainability & Risk Officer)

Mr. Christopher Michael Smith BSc (CEO & Director)

Products / Services

Biotechnology, Genetics, Health Care, Health Diagnostics, Medical, Pharmaceutical

Number of Employees

1,000 - 20,000

Address

Fort Myers, Florida, United States

Established

1998-01-01

Company Registration

SEC CIK number: 0001077183

Revenue

100M - 500M

Traded as

NEO

Website

https://www.neogenomics.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

NeoGenomics

Rank#4649

Market Cap2.36B

CountryUnited States

Summary

History

Mission

We save lives by improving patient care.

Vision

By providing uncompromising quality, exceptional service and
innovative solutions, we will be the world’s leading cancer testing and information company.

References

https://en.wikipedia.org/wiki/NeoGenomics

https://in.investing.com/equities/neogenomics-inc

https://finance.yahoo.com/quote/NEO/profile?p=NEO

https://www.comparably.com/companies/neogenomics-laboratories/mission

https://www.crunchbase.com/organization/neogenomics-laboratories

https://sec.report/CIK/0001077183

https://companiesmarketcap.com/

https://www.neogenomics.com

Leadership team

Mr. George A. Cardoza (Pres & COO of Lab Operations)

Ms. Kathryn B. McKenzie (Interim Chief Culture Officer, Chief Sustainability & Risk Officer)